Incannex Healthcare Achieves Interim Milestone in Phase 2 Psilocybin Clinical Trial

Australian pharmaceutical company, Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), has achieved its interim milestone of 29 patients completing primary endpoint assessments in a Phase 2 trial evaluating psilocybin-assisted psychotherapy for anxiety.

Incannex is developing proprietary medicinal cannabinoid products and psychedelic medicine therapies for unmet medical needs. Psilocybin-assisted psychotherapy has shown promise in the treatment of a number of mental health conditions.

Highlights

  • The 10-week trial is designed to assess the safety and efficacy of Incannex’s unique psilocybin program in an active placebo-controlled study.
  • Quality of life and other aspects of mental and physical health will be assessed, along with safety and efficacy.
  • An independent Data Safety Monitoring Board has commenced analysis of the interim study data.

Incannex is positioned to be one of the first companies in the world to develop a proprietary psychedelic therapy.

About the Author:

Applied Therapeutics Charts Path Forward After FDA Setback, Eyes European Approval and Pipeline Expansion

Editor Prism MarketView

PRISM Market View Alerts

Get your dose of PRISM Market
View news, right in your inbox

Mailchimp Signup

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt
ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida.